|
Published by: SMI Publishing, Ltd
Published: Jan. 16, 2002
Table of Contents
- Day 1
- 8.30 Registration and Coffee
- 9.00 Chairman's Opening Remarks
- Dr Abdelazize Laoui, Head, Chemoinformatics, Sanofi-Aventis.
- 9.10 BIOINFORMATICS IN THE PHARMA INDUSTRY: FROM PROMISE TO DELIVERY
- The coming of age for bioinformatics
- Lessons learnt from the honeymoon
- Critically assessing the value of bioinformatics
- Balancing facilitation and exploitation
- Evolving bioinformatics into a powerful research tool
- Towards a biological data nexus
- Dr Carl Firth, Associate Director, Bioinformatics, AstraZeneca .
- 9.40 INDUSTRY TRENDS
- Emerging commercial paradigms in bioinformatics
- The bioinformatics market
- Information and resources
- Bioinformatics software sector
- Database and services sectors
- Bioinformatics ASPs, internet portals and information integration
- Bioinformatics consulting services
- Dr Tim Clark, Vice President, Informatics, Millennium Pharmaceuticals.
- 10.20 THE NEW AGE OF DIGITAL BIOLOGY
- Applications and perspectives
- Automated workflows
- Data management: workflows versus knowledge
- Digital biology data explosion
- Meta-data defines data quality
- From data to biology
- The impact on drug discovery
- Dr Seth Taylor, President, Molecularware.
- 11.00 Morning Coffee
- 11.20 LIFE-SCIENCE INFORMATICS
- We have integrated data, now what?
- Tell me everything we need to know about…
- integrating data from disparate sources
- What’s new
- alerting user(s) to updated information
- Who would know about this:
- enabling collaboration
- eliminating duplication
- I wonder if
- testing ideas with a novel ad-hoc query tool
- What should I do next
- workflow and risk management in an integrated environment
- Mr Andrew Payne, Business Analyst, Netgenics UK Ltd.
- 12.00 STATISITCAL ANALYSIS OF HIGH DENSITY AFFYMETRIX GENECHIP DATA AND BEYOND
- Moving from an empirically based analysis algorithum to a statistically based algorithum
- Why Affymetrix derived a new method to analyse their data?
- How did Affymetrix derive and test statistically based algorithm
- The effect of the new algorithm on GeneChip probe array data
- Successful methodologies to mine high density GeneChip probe array data
- Dr Fiona Brew, Field Applications Manager, Europe, Affymetrix.
- 12.40 Lunch
- 1.40 COMPUTATIONAL PRIORITIZATION
- Human genome for experimental validation
- Using human genome sequences to generate a range of gene predictions sorted by type and depth of evidence
- Multiple ab-intio gene finders and sequence-based association of experimental evidence optimising the ability to predict human genes
- Case study- BLASTN/SIM4 mapping of clustered human and mouse expressed DNA sequences to the genome
- Genome annotation using a rule-based system
- Deriving estimates of sensitivity and specificity for different classes of gene predictions
- Inclusion of multiple high sensitivity prediction methods is vital to direct future experimental investigation for possible novel genes
- Dr Nick Tisnoremas, Vice President, Genomics, DoubleTwist.
- 2.20 THE GENELYNX SYSTEM
- An integrated portal to the human genome
- Integrating human gene-specific information
- Interface to public domain resources
- Establishing hyperlinks to intranet resources
- Example: Annotation of microarrays
- Generation of gene summaries
- Dr Wyeth Wasserman, Group Leader, Gene Regulation Bioinformatics, Pharmacia.
- 3.00 BIOINFORMATICS
- A data management perspective
- Genomic data volume and heterogeneity
- Modelling genomic data: characteristics
- Data-acquisition vs data warehousing
- Genomic data integration issues
- Solutions and outlook
- Mr Victor Markowitz, CIO & Sr VP, data management systems, Gene Logic Inc.
- 3.40 Afternoon Tea
- 4.00 COMBINATORIAL AND INTEGRATIVE BIOINFORMATICS
- New frontiers in bioinformatics
- Systematic genome analysis
- Functional and structural classification
- Functional analysis employing independent data types
- Integration of heterogenous data sources
- Mr Matthias Fellenberg, Project Manager, Scientific Bioinformatics, Biomax.
- 4.40 BIOINFORMATICS- BRIDGING ISLANDS OF INFORMATION
- Integrating solutions for targeted data and information exchange
- Identifying core processes in target identification
- The islands of information
- Automated processes
- Partnering for specialized analytics
- Communication between partnered resources
- Beyond automation
- Putting it all together
- Dr David Fenyo, , ProteoMetrics.
- 5.20 Chairman's Closing Remarks and Close of Day One
- Day 2
- 8.30 Re-registration and Coffee
- 9.00 Chairman's Opening Remarks
- 9.10 BIOINFORMATICS IN THE DRUG DISCOVERY PROCESS
- Initiation of the drug discovery pipeline
- From sequence to active molecules
- Target selection and validation
- What is a drugable target?
- Hit generation and beyond
- Case Study
- Dr Vladimir Saudek, Senior director, bioinformatics, Incyte Genomics Limited.
- 9.40 DRUG DISCOVERY THROUGH DIGITAL SYSTEMS BIOLOGY
- A new model for life sciences discovery
- Genomic information will have the most value when contexts of disease, tissue and genetics are included
- Merging genomics, proteomics, and metabolomics data in order to uncover mechanisms
- Elucidating molecular pathways from multiple data sources
- Extending proteomics to maximize value and significance
- Moving from correlated facts to casual models of action
- Using models to identify biomarkers and next generation targets
- Dr Eric Neumann, Vice president, Bioinformatics, Beyond Genomics, Inc..
- 10.20 MINING INTEGRATED DRUG AND TARGET DISCOVERY DATA
- A blueprint and sample applications of an in silico drug and target discovery research assistant
- Introduction a role for data mining in science: the in silico research assistant
- Data Preparation building integrated and mineable data representations: the importance of multi-relational databases
- Data Mining
- - exploring an integrated database of biological, chemical and clinical data
- - approaching the data from multiple angles (bio,chemo,clinical)
- - scanning the best-of-breed data mining technologies for an optimal solution
- - using relational data mining to discover patterns in multi-relational data
- Sample bioinformatics applications
- Dr Luc Dehaspe, Chief Scientific Officer, PharmaDM.
- 11.00 Morning Coffee
- 11.20 CHEMOINFORMATICS LOOKS TO BIO
- Moving towards drug discovery informatics
- Developing new drug discovery informatics solutions; designed to deal with the challenges in today’s data-rich environment
- Challenges arising from the volume, diversity and variable quality of data being generated
- Data pipelining has emerged as a practical technology for accelerating the discovery process
- Bridging the gap between bioinformatics and chemoinformatics quickly
- Implementing a new paradigm in drug discovery: Chemical Biology
- Case Study: Examples of application to the identification of Farnesyl transferase inhibitors and G-quadruplex DNA ligands
- Dr Abdelazize Laoui, Head, Chemoinformatics, Sanofi-Aventis.
- 12.00 BIOINFORMATIC SYSTEMS
- High-throughput industrial scale proteomics
- Proteomics is the drug discovery and development technology of choice for the 21st century
- High throughput proteomics is highly automated
- Data is automatically acquired form mass spectrometers and other instruments
- Proteomics data is combined with protein sequences. DNA sequences and other genome related data to create complex databases
- Value is obtained from these databases using bioinformatic and data mining tools
- Mr Jonathan Sheldon, C T O, Confirmant Ltd..
- 12.40 Lunch
- 1.40 LEVERAGING BIOINFORMATICS FOR DRUG DISCOVERY
- Deriving the most value from genomics
- Value of an accurately assembled and annotated genome
- The power of comparative genomics
- Understanding gene regulation
- The effects of human variation on drug development
- Linking genomics and proteomics
- How bioinformatics can support target validation
- Dr Anthony Kerlavage, Sr. Director, Bioinformatics, Celera Genomics.
- 2.20 INFORMATICS- DRIVEN DRUG DISCOVERY
- Rational exploitation of genomic and chemical information for the discovery of novel therapeutics
- Discovery of drugs against novel targets derived from genomic information is a highly inefficient and attritional process
- The pivitol step is selecting the most drugable and biologically valid targets from the genome
- A unifying informatics framework that reconciles biological and chemical information
- Protein and small-molecule structure provides the foundation for this framework
- Informatics must be applied on a genomic scale for target selection and subsequent drug discovery steps to be truly rational
- Heavy investment in infrastructure and automated, robust, scaleable systems based on powerful algorithms and engineering
- The practice of drug discovery needs to be based on informatics and information generation which is transformed to ‘gene-to-drug pipeline’ thinking
- Dr Malcolm Weir, CSO, Inpharmatica.
- 3.00 BIOINFORMATICS IN RESEARCH
- Role in discovery research
- Bioinformatics: The scientific challenge
- The emerging market for bioinformatics
- The evolution of bioinformatics: post-genome informatics
- High-throughput research: data integration, genomic integration, and laboratory productivity
- The discovery R & D value chain
- Applied bioinformatics: A practical example
- The impact of bioinformatics on the pharmaceutical and biotech industries
- Mr Steve Lincoln, CSO & Sr VP, product development, InforMax Inc..
- 3.40 Afternoon Tea
- 4.00 INTELLECTUAL PROPERTY RIGHTS
- Protecting your genetic discoveries
- Types of protection- patents, database rights or confidential information?
- When and what to patent- tools themselves or the results of their use?
- Current issues in gene patenting
- Current issues in bioinformatics patenting
- Mr Trevor Cook, Partner / Pharma & Biotech IP Law, Bird & Bird.
- 4.40 REGULATORY ISSUES
- Legal aspects
- Regulating the new genetic era
- Licensing procedures
- Potential value of licences on product life-cycle protection
- The future regulatory environment
- Mr Simon Harper, Senior Associate, Lovells.
- 5.20 Chairman's Closing Remarks and Close of Conference
AbstractThe pharmaceutical industry is undergoing a massive transformation, one in which computing and software companies are playing a major role in the acceleration of new products. Bioinformatics is becoming increasingly essential to all aspects of drug development from target discovery to target validation. The evolution to this new era of discovery has significant implications for all companies seeking better methods for aggregating, accessing, manipulating and analysing data with those pharmaceutical companies embracing informatics being propelled towards success. Bioinformatics now holds the key to separating the winners from the losers.
Bioinformatics in the 21st Century aims to explore the current key issues within the industry and the opportunities for the future of drug design. Topics covered at the conference will include data management and streamlining in a secure environment and the practical application of bioinformatics in drug design in areas such as genomics and proteomics. The future economic, regulatory and legal issues generated by the explosion of bioinformatics will also be covered.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
